Oncopeptides AB (publ)

LSE:0RN4 Stock Report

Market Cap: SEK 404.1m

Oncopeptides Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 0RN4?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders653,7500.304%
VC/PE Firms27,296,25512.7%
Institutions44,580,20520.7%
General Public142,656,03666.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 18 shareholders own 34.52% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.7%
Odlander, Fredrikson & Co. AB
27,296,255SEK 51.3m0%5.22%
4.94%
Redmile Group, LLC
10,635,201SEK 20.0m45.3%0.18%
4.85%
Nordnet Pensionsförsäkring Ab, Asset Management Arm
10,438,896SEK 19.6m0%0.32%
4.61%
Avanza Fonder AB
9,916,230SEK 18.6m-28.8%0.02%
3.85%
Industrifonden
8,285,258SEK 15.6m0%8.19%
2.1%
Handelsbanken Asset Management
4,520,183SEK 8.5m0%no data
0.5%
SEB Investment Management AB
1,068,552SEK 2.0m0%no data
0.35%
FCG Fonder AB
763,012SEK 1.4m0%0.01%
0.24%
Storebrand Fonder AB,
526,824SEK 989.4k0%no data
0.23%
Per Wold-Olsen
497,616SEK 934.5k0%no data
0.065%
Skandia Fonder AB
140,274SEK 263.4k0%no data
0.047%
Jarl Jungnelius
101,042SEK 189.8k0%no data
0.026%
Cecilia Wennborg
55,092SEK 103.5k0%no data
0.0065%
State Street Global Advisors, Inc.
13,997SEK 26.3k66.1%no data
0.004%
Fund Development & Advisory AG
8,500SEK 16.0k0%no data
0.002%
Danske Bank A/S, Asset Management Arm
4,326SEK 8.1k0%no data
0.0019%
DFP Deutsche Finanz Portfolioverwaltung GmbH
4,000SEK 7.5k0%no data
0.0002%
Nordea Investment Management, AB
437SEK 808.20%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/08 23:34
End of Day Share Price 2025/05/08 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oncopeptides AB (publ) is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Erik HultgårdCarnegie Investment Bank AB
Patrik LingDNB Markets
Peter WelfordJefferies LLC